Capability details
Baxter`s BioScience business is a leader in recombinant and plasma-based protein replacement therapies to treat hemophilia and other bleeding disorders. BioScience core franchises include: Hemophilia, Biotherapeutics, BioSurgery and Vaccines. Products represent approximately 45 percent of annual sales, totaling $5.7 billion in 2010.